Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vellus Hair

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Vellus Hair. Displaying page 1 of 1.
    EudraCT Number: 2010-018291-25 Sponsor Protocol Number: CRC-AGA02 Start Date*: 2010-08-25
    Sponsor Name:Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC
    Full Title: INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY I...
    Medical condition: Otherwise healthy men with androgenetic alopecia (Hamilton-Norwood Scale IIIvertex to VI) in the temple and vertex area.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000613-22 Sponsor Protocol Number: CO-150225133959-HRCT Start Date*: 2018-10-15
    Sponsor Name:Johnson & Johnson Consumer Inc
    Full Title: A 16 Week, Single-center, Randomized, Placebo- and Active-controlled Proof of Principle Study to Assess the Efficacy and Safety of a 5% Minoxidil Topical Gel Formulation in Male subjects with Andro...
    Medical condition: Alopecia Androgentica
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004305-26 Sponsor Protocol Number: FCS-003 Start Date*: 2020-01-29
    Sponsor Name:Follicum AB
    Full Title: A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers...
    Medical condition: Alopecia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001770-33 Sponsor Protocol Number: CRC-AGA01 Start Date*: 2008-05-15
    Sponsor Name:Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC
    Full Title: INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) ...
    Medical condition: Women above 18 years old with slightly to moderate androgenetic alopecia (AGA), otherwise in general good health. The subjects have to show a female pattern type of AGA, Savin scale D3-D6 and a hai...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000950-78 Sponsor Protocol Number: CB-03-01/35 Start Date*: 2019-08-20
    Sponsor Name:Cassiopea S.p.A.
    Full Title: A Phase 2, multicenter, prospective, randomized, double-blind, Minoxidil and vehicle controlled, dose-ranging study to evaluate the efficacy and safety of CB-03-01 (Cortexolone 17α-propionate) solu...
    Medical condition: Female Androgenic Alopecia (AGA) is scalp hair loss that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. In the hair follicle, testosterone is converted ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017415-16 Sponsor Protocol Number: AFCT-14/2009 Start Date*: 2010-07-26
    Sponsor Name:Dr. August Wolff GmbH & Co KG Arzneimittel
    Full Title: A Phase III, single-center, randomized, double-blind, parallel group, placebo-controlled study of Alpicort F in the treatment of chemotherapy induced alopecia in women
    Medical condition: Chemotherapy induced alopecia in women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003809-17 Sponsor Protocol Number: FCS-002 Start Date*: 2018-01-04
    Sponsor Name:Follicum AB
    Full Title: A randomised, double-blind, placebo-controlled phase 2 trial of FOL-005 to investigate efficacy on hair growth on scalp skin in healthy volunteers.
    Medical condition: Alopecia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003733-23 Sponsor Protocol Number: CB-03-01/34 Start Date*: 2017-05-09
    Sponsor Name:Cassiopea S.p.A.
    Full Title: A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE...
    Medical condition: AGA (androgenic alopecia) is scalp hair loss that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. In the hair follicle, testosterone is converted by 5α-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019881-96 Sponsor Protocol Number: MINALO3005 Start Date*: 2010-11-19
    Sponsor Name:Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
    Full Title: A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. VEHICLE IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOP...
    Medical condition: FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10068168 Androgenetic alopecia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018109-29 Sponsor Protocol Number: MINALO3004 Start Date*: 2010-07-05
    Sponsor Name:Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
    Full Title: A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (AND...
    Medical condition: FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10068168 Androgenetic alopecia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005573-36 Sponsor Protocol Number: DC0120LE202 Start Date*: 2015-06-18
    Sponsor Name:Pierre Fabre Dermatologie represented by the Institut de Recherche Pierre Fabre (IRPF)
    Full Title: Assessment of the efficacy of a new formulation of minoxidil (DC120) on hair growth, in a minizone model in androgenetic alopecia in men
    Medical condition: androgenetic alopecia
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002671-10 Sponsor Protocol Number: 203820 Start Date*: 2016-12-20
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two-part trial to evaluate the safety, tolerability, clinical effect and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 07:55:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA